Rx License-Rx

TAB-352

Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus

Available for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J Virol. 1989 Jul;63(7):2941-2950 ( PubMed abs ). The MAbs that are available for licensing are the following: 1129, 1153, 1142, 1200, 1214, 1237, 1112, 1269, and 1243. One of these MAbs, 1129, is the basis for a humanized murine MAb (see U.S. Patent 5,824,307 to humanized 1129 owned by MedImmune, Inc.), recently approved for marketing in the United States. MAbs in the panel reported by Beeler et al. have been shown to be effective therapeutically when administered into the lungs of cotton rats by small-particle aerosol. Among these MAbs several exhibited a high affinity (approximately 10 9 M -1 ) for the RSV F glycoprotein and are directed at epitopes encompassing amino acid 262, 272, 275, 276 or...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Infectious Disease

Indication: Infectious Disease

Modality: Biologic

Focus tags: Infectious Disease, Immunology

Technology tags: Biologic

Mechanism:

Development stage: Commercial-Ready

Patent status: Research Material

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Infectious Disease. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be commercial-ready and is associated with National Institutes of Health. The practical first use case is Infectious Disease. Public description: Available for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion.

What is exciting

More mature than a typical academic invention: Prior human, regulatory, or deployment evidence can shorten diligence and make strategic buyers more comfortable.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Adoption and buyer pull must be proven: Commercial-ready tools still need workflow fit, budget owner clarity, reimbursement or procurement logic, and competitive differentiation.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: Infectious Disease

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.